Forward Looking Statements and Disclaimer

This presentation has been prepared by VolitionRx Limited solely for informational purposes. Certain of the information used in this presentation has been obtained from independent industry sources, publications or research reports. This information has been obtained from sources we believe to be reliable. However, we have not independently verified such information. Some of the statements in this presentation and otherwise made by the Company may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as expects, anticipates, intends, plans, aims, targets, believes, seeks, estimates, optimizing, potential, goal, suggests, and similar expressions identify forward-looking statements. All statements other than historical facts are forward-looking statements.

Forward-looking statements relate to, among other things, the effectiveness of the Company’s bodily fluid based diagnostic tests, as well as the Company’s ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company’s actual results may differ materially from those indicated by forward-looking statements, due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include, but are not limited to, the Company’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market, a failure by the marketplace to accept the products in the Company’s development pipeline, or any other diagnostic products the Company might develop. The Company will face fierce competition, and the Company’s intended products may become obsolete, due to the highly competitive nature of the diagnostics market and its rapid technological change, and other risks identified on the Company’s most recent annual report on form 10-K, and quarterly reports on form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission.

The statements contained in the presentation are based on current expectations, estimates, and projections about the Company’s business, based in part on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this presentation and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, Nu.Q® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this presentation are the property of their respective owners.
Our Mission

The dedicated team at Volition is a collective force of distinct individuals with a shared goal – to save lives by revolutionizing the way disease, and especially cancer, is diagnosed throughout the world, through routine blood tests.
Purpose-built, state of the art research and development facility in Belgium. This facility has provided us with increased capacity and capability; we now have additional freezer space, automates and importantly an expanded scientific team.
Key Financials

NYSE American: VNRX
Market Cap: $77.8m*
52 week range: $1.44-$4*
Cash-on-hand: $16.4m*
Avg. Quarterly Burn: Approx. $3.9m*

*As of 30th Sept, 2018
Diagnostic healthcare company with a suite of easy to use blood-based cancer tests under development

We believe that simple to use blood tests are the best way to achieve improved levels of compliance (>80%) for Colorectal Cancer (CRC) screening

Large ongoing clinical trials with over 60,000 samples

Broad intellectual property portfolio, including 5 granted US patents to date

Potential indication expansion with base platform including CRC, Pancreatic, Prostate and Lung
Investment Highlights

Product

Anticipated colorectal cancer launch
- Europe 2019 / Asia 2020, US 2020/2021

Large scale Colorectal cancer studies underway globally
- Europe 30,000+ subjects
- U.S. 13,500+ subjects
- Asia 7,000+ subjects

27-cancer study underway, preliminary data expected H1 ‘19

Prostate cancer encouraging proof of concept results reported

Research Use Only Kit Range launched ‘18 with Active Motif. Revenue from Q3 ‘18

Endometriosis study ongoing - results H2 ‘18

Pilot studies in Veterinary uses underway
Cancer - The ongoing problem

1 in 7 deaths worldwide is due to cancer.

Cancer is the second leading cause of death worldwide with over 14.1 million new cases diagnosed each year. This causes over 8.2 million deaths worldwide.

In the U.S., three new cases of cancer are diagnosed and one person dies of a cancer-related death every minute.

One death every minute.
Given the growing and more importantly aging population, cancer’s burden is expected to worsen. It is expected that by 2030, there will be over 21 million new cases of cancer each year. This would result in approximately 13 million cancer-related deaths, more than the population of Belgium.
Why should cancer be screened differently?

<table>
<thead>
<tr>
<th>Disease</th>
<th>Frontline Screening / Diagnostic Blood Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>![ ]</td>
</tr>
<tr>
<td>Cardiovascular function</td>
<td>![ ]</td>
</tr>
<tr>
<td>Kidney function</td>
<td>![ ]</td>
</tr>
<tr>
<td>Thyroid function</td>
<td>![ ]</td>
</tr>
<tr>
<td>Liver function</td>
<td>![ ]</td>
</tr>
<tr>
<td>Reproductive function</td>
<td>![ ]</td>
</tr>
<tr>
<td>Infectious disease (HIV/Hepatitis)</td>
<td>![ ]</td>
</tr>
<tr>
<td>Inflammatory disease</td>
<td>![ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-Ray</td>
</tr>
<tr>
<td>Mammography</td>
</tr>
<tr>
<td>MRI Scan</td>
</tr>
<tr>
<td>CT Scan</td>
</tr>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Colonoscopy</td>
</tr>
<tr>
<td>Flexible sigmoidoscopy</td>
</tr>
<tr>
<td>Fecal test</td>
</tr>
<tr>
<td>Pap Smear</td>
</tr>
</tbody>
</table>
• Nu.Q could represent a powerful step change in rethinking the approach to cancer.

• Nu.Q projected to be a simple solution to the challenging problem of early cancer diagnosis.

• Nu.Q run as simple low-cost ELISA technology, which can utilize other tests in panels (e.g.; CEA, PSA, CA125) for even higher accuracy.
Nu.Q™ – How it works

The genome is 3 billion base pairs

If uncoiled it would measure 5 feet long. Every 150 base pairs of DNA are wrapped around a nucleosome to form a DNA-Nu complex

Each individual ‘bead’ is called a nucleosome

Nucleosomes consist of DNA and histone proteins. Histones and DNA are subjected to a variety of epigenetic modifications

The DNA in every cell is wound around protein complexes in a “beads on a string” structure

Cancer leads to cell death which results in fragmentation and release of nucleosomes into the blood
When a cancer cell dies, the nuclear components are metabolized into 20 million individual DNA-Nu complexes and released into circulation. A cancer mutation will occur in one of the DNA-Nu complexes.

Nu.Q targets **ALL** of the 20 million circulating DNA-Nu complexes because nucleosome modifications occur globally.

**ctDNA sequencing methods (in development) must target that one in 20 million DNA-Nu complex.**

We look at the whole haystack, not just the needle.

Volition has developed a suite of novel, **routine** blood tests for epigenetically altered circulating nucleosomes as biomarkers in cancer. We can incorporate other off-patent, low-cost ELISA tests into our panels (e.g.; CEA) for improved accuracy.
Product Strategy

We plan to develop multiple products across a range of cancers falling into the following categories:

- **Front Line Screening Tests**
  - For asymptomatic subjects for the most prevalent cancers
  - E.g. lung, colorectal, gastric and breast cancers.

- **Triage Tests**
  - To work in conjunction with existing tests to improve sensitivity and/or specificity
  - E.g. with fecal tests for colorectal cancer or with low dose CT scans for lung cancer.

- **Frontline Diagnostic / Adjunct Diagnostic Tests**
  - To aid the diagnosis of diseased and/or treatment selection in symptomatic patients and/or high-risk patients
  - E.g. Type II diabetes patients for pancreatic cancer.

- **Disease Monitoring Tests**
  - To help monitor and/or identify the recurrence of a disease
  - E.g. prostate cancer.
Intellectual Property

- Believe to be the only company working on ELISA measurement for epigenetically modified circulating nucleosomes
- 17 patent families
- Five patents granted in the U.S., 12 pending
- Four patents granted in the E.U., 13 pending
- Further unpublished patents in growing IP portfolio
- Protection expected through or least to 2031 for products using the Nu.Q-X, Nu.Q-V and Nu.Q-A technologies
Initial Focus on Colorectal Cancer

700,000 Deaths worldwide each year

“Cancer screening tests can improve survival and decrease mortality by detecting cancer at an early stage when treatment is more effective.”

American Cancer Society
If screening participation can be increased to 80%, then the cancer death rate can be reduced by up to 33%, saving over 200,000 lives in the US alone by 2030.\textsuperscript{11}

“We believe the only way to achieve this is with a routine blood test.”

Jake Micallef
Chief Scientific Officer
We believe blood tests for cancer are a 'Holy Grail'

<table>
<thead>
<tr>
<th></th>
<th>Nu.Q™</th>
<th>Scanning/Colonoscopy</th>
<th>Cologuard®</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ease of use</strong></td>
<td>• Yes, regular blood draw</td>
<td>No</td>
<td>Not particularly. Test is self administered so compliance is not guaranteed.</td>
</tr>
<tr>
<td></td>
<td>• Can be performed using same vial of blood collected for cholesterol / virtually any standard blood test</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No special order/drawer/shipping -- simply check off another box on the standard requisition form</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Risk to Patient</strong></td>
<td>None/minimal</td>
<td>Endoscopy or radiation tissue damage possible</td>
<td>None</td>
</tr>
<tr>
<td><strong>Convenience</strong></td>
<td>Can be done anytime at doctor's office</td>
<td>Specific hospital appointment required, often time off work required. Uncomfortable/unpleasant</td>
<td>Dr. visit required for prescription, contact with customer care team required, drop off or home pick up of test required</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>Usually low cost</td>
<td>Usually high cost</td>
<td>Medium cost</td>
</tr>
<tr>
<td><strong>Patient compliance</strong></td>
<td><strong>Blood test compliance 99.5%</strong>&lt;sup&gt;12&lt;/sup&gt;</td>
<td>For Colorectal Cancer approx. 60% participation</td>
<td>65% completion of shipped tests&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Current data on Nu.Q™ platform: Colorectal Cancer

In a prospective trial of 58 subjects a panel of 4 Nu.Q assays demonstrated CRC detection accuracy of 74% at 90% specificity and detected all stages of the cancer, including 75% of early stage I cancers.

By using an age-adjusted algorithm the accuracy of CRC detection increased to 91% at 90% specificity\(^\text{14}\).

In a larger study involving 680 asymptomatic subjects a small panel of 3 ELISA assays detected\(^\text{15}\):

- 80% of stage I cancers with 78% specificity
- 66% of high-risk adenomas

The *first* data for a *routine* blood test to identify early……when treatment can be more successful
Current Data on the Nu.Q™ platform

Prostate Cancer
• A panel of 5 assays (including PSA) in a pilot study of 84 men identified 94% of high-grade prostate cancers that require treatment, as defined by the Gleason Score at 88% specificity.
• This compares with just 33% identified by PSA alone.¹⁶

Pancreatic cancer
• A panel of 4 Nu.Q assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 90% specificity, published in Clinical Epigenetics.¹⁷

Lung Cancer
• A panel of 4 Nu.Q assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.¹⁸
## Ongoing Trials

<table>
<thead>
<tr>
<th>Institution</th>
<th>Condition</th>
<th>Sample Collection</th>
<th>Cohort</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Detection Research Network of the U.S. National Cancer Institute</td>
<td>Colorectal Cancer</td>
<td>9,000 Prospective 4,600 Retrospective</td>
<td>13,500 + Screening population</td>
<td>Collection ongoing to ‘20</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal Cancer</td>
<td>Prospective</td>
<td>14,000 Screening population</td>
<td>Collection completed. Results expected ‘19</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal Cancer</td>
<td>Prospective, Longitudinal</td>
<td>30,000 Screening population</td>
<td>Collection completed</td>
</tr>
<tr>
<td>National Taiwan University</td>
<td>Colorectal Cancer</td>
<td>Prospective</td>
<td>5,000 Screening Population</td>
<td>Collection ongoing</td>
</tr>
<tr>
<td>National Taiwan University</td>
<td>Colorectal Cancer</td>
<td>Prospective</td>
<td>2,000 Symptomatic Patients</td>
<td>Collection ongoing</td>
</tr>
<tr>
<td>University of Bonn</td>
<td>27 most prevalent cancers</td>
<td>Prospective</td>
<td>4,500 subjects</td>
<td>Collection completed. Results expected ‘19</td>
</tr>
<tr>
<td>German Cancer Research Center (DKFZ)</td>
<td>Pancreatic Cancer</td>
<td>Retrospective</td>
<td>750 subjects</td>
<td>Collection completed. Results expected 2018/19</td>
</tr>
</tbody>
</table>
Colorectal Cancer Pipeline

<table>
<thead>
<tr>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Anticipated Launch</td>
<td>EU Anticipated Launch</td>
<td>EU Anticipated Launch</td>
<td>EU Anticipated Launch</td>
<td>UI Anticipated Launch</td>
</tr>
<tr>
<td>Asia Anticipated Launch</td>
<td>Asia Anticipated Launch</td>
<td>Asia Anticipated Launch</td>
<td>U.S. Anticipated Launch</td>
<td>U.S. &amp; Asia Anticipated Launch</td>
</tr>
</tbody>
</table>

Volition © 2017
Regulatory Strategy

**U.S.**

- 13,500 Screening population trial with the Early Detection Research Network of the U.S. National Cancer Institute
- 510k for symptomatic Nu.Q product

**EU**

- CE Mark and launch in the EU projected 2019

**ASIA (Excluding China)**

- First large trial underway (Q2 2018)
- Each country will require registration with the appropriate local authority
- With CE mark, the company believes that most countries will use the CE mark and accompanying clinical data as a basis of evaluation. Other countries may require ancillary validation trials to be added on to the submission for approval.
Research Use Only Kits

- Global Sales and Distribution Agreement with Active Motif
- A complete solution to profiling nucleosomes - from cell to serum
- Applications include biomarker discovery in oncology, inflammatory conditions, infectious disease and transplant rejection
- Simple immunoassay approach requiring low sample volumes (typically 10-20uL)
- Can be used on tissue culture or serum
- Kits for other biofluids including plasma, urine, saliva and cerebrospinal fluid expected to be available soon

**Rapid**
epigenetic profiling in disease models, preclinical testing and clinical trials

**Preserving** samples
Low input volume

**Early revenue potential**
Anticipated colorectal cancer launch
- Europe 2019 / Asia 2020, US 2020/2021

Large scale colorectal cancer studies underway globally
- Europe 30,000 + subjects
- U.S. 13,500+ subjects
- Asia 7,000+ subjects

27-cancer study underway, preliminary data expected H1‘19

Prostate cancer encouraging proof of concept results reported

Research Use Only Kit Range launched ‘18 with Active Motif. Revenue from Q3 ‘18

Endometriosis study ongoing - results H2 ‘18

Pilot studies in Veterinary uses underway
Diagnostic healthcare company with a suite of easy to use blood-based cancer tests under development

We believe that simple to use blood tests are the best way to achieve improved levels of compliance (>80%) for Colorectal Cancer (CRC) screening

Large ongoing clinical trials with over 60,000 samples

Broad intellectual property portfolio, including 5 granted US patents to date

Potential indication expansion with base platform including CRC, Pancreatic, Prostate and Lung
Executive Team

**Cameron Reynolds MBA, President & Chief Executive Officer** - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a B.Com. and an MBA.

**David Vanston MBA FCCA, Chief Financial Officer** - David has 20 years of financial management experience and recently held the position of Vice President Europe, Finance for Monster Worldwide, Inc. He has managed and overseen the accounting, finance, tax, treasury, financial planning and analysis of numerous businesses. He is a certified chartered accountant and holds an MBA from Warwick Business School.

**Jake Micallef PhD MBA, Chief Scientific Officer** - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology, and an MBA from Imperial College Management School.

**Louise Day, Chief Marketing and Communications Officer** - Louise has more than 20 years of marketing, sales and leadership experience. Since 2011, she has served as Director of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including roles in Paris and New York. She holds a BA in Business Studies from Sheffield Hallam University.
Executive Team

**Jason Terrell MD, Chief Medical Officer & Chief Executive Officer of Volition America, Inc.** - Jason has expertise in clinical medicine and in laboratory diagnostics in the areas of business development, clinical trials, regulatory affairs and commercialization strategies. He was educated at Hardin-Simmon University where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his MD from the University of Texas Medical School an affiliate of the MD Anderson Cancer Center.

**Gaetan Michel PhD, Chief Executive Officer of Belgian Volition SPRL** - Gaetan has over 10 years of experience in production management. Previously he has held positions such as project manager and production manager in proteomics at Advanced Array Technology and production and process development manager at KitoZyme. He has expertise in establishing production processes and equipment. He has a PhD in Biochemistry from the University of Namur.

**Jasmine Kway PhD, Chief Executive Officer, Singapore Volition** - Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. She has worked with numerous health and regulatory bodies. She has successfully commercialised and expanded companies into the Asian markets. Jasmine has a B.Eng and a PhD in Oceanography from the National University of Singapore.

**Rod Rootsaert LLB, Corporate Secretary** - Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a LLB from the University of Western Australia.

**Scott Powell PhD, EVP, Investor Relations & CFO of Volition America, Inc.** - Scott has nearly 20 years of experience in the U.S. capital markets and investor relations. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.
References

The contents of the websites set forth below are for reference only and are not incorporated by reference into these presentation materials and the company assumes no obligation for the accuracy or completeness of such information.


References


16. Data on file


Thank you for your interest in Volition

For more information please visit our website and watch our Corporate Video at www.volitionrx.com or email mediarelations@volitionrx.com